UY31202A1 - BIOMARKERS FOR THE SELECTION OF PATIENTS FOR TREATMENT WITH CB1R ANTAGONISTS - Google Patents

BIOMARKERS FOR THE SELECTION OF PATIENTS FOR TREATMENT WITH CB1R ANTAGONISTS

Info

Publication number
UY31202A1
UY31202A1 UY31202A UY31202A UY31202A1 UY 31202 A1 UY31202 A1 UY 31202A1 UY 31202 A UY31202 A UY 31202A UY 31202 A UY31202 A UY 31202A UY 31202 A1 UY31202 A1 UY 31202A1
Authority
UY
Uruguay
Prior art keywords
treatment
patients
cb1r
selection
biomarkers
Prior art date
Application number
UY31202A
Other languages
Spanish (es)
Inventor
Sven Sjogren
Cecilia Karlsson
Bjorn Acrlsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY31202A1 publication Critical patent/UY31202A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/02—Nutritional disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La invención permite la selección de pacientes necesitados de tratamiento con un fármaco antagonista del receptor cannabinoide (CB1R), en base a niveles de ligandos endocannabinoides circulantes. Esta es capaz de identificar mamíferos que necesitan tratamiento para perder, mantener o prevenir la ganancia de peso con un fármaco antagonista de CB1R que comprende determinar el nivel de al menos un ligando endocannabonoides circulante en el mamífero, por medio del cual se predice una probabilidad de respuesta al mismo y permite identificar pacientes que son más o menos propensos a responder favorablemente al tratamiento, evitando así tratamientos innecesarios y efectos colaterales.The invention allows the selection of patients in need of treatment with a cannabinoid receptor antagonist drug (CB1R), based on circulating endocannabinoid ligand levels. This is able to identify mammals that need treatment to lose, maintain or prevent weight gain with a CB1R antagonist drug that comprises determining the level of at least one circulating endocannabonoid ligand in the mammal, through which a probability of response to it and allows identifying patients who are more or less likely to respond favorably to treatment, thus avoiding unnecessary treatments and side effects.

UY31202A 2007-07-03 2008-07-02 BIOMARKERS FOR THE SELECTION OF PATIENTS FOR TREATMENT WITH CB1R ANTAGONISTS UY31202A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94773307P 2007-07-03 2007-07-03

Publications (1)

Publication Number Publication Date
UY31202A1 true UY31202A1 (en) 2009-01-30

Family

ID=39713772

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31202A UY31202A1 (en) 2007-07-03 2008-07-02 BIOMARKERS FOR THE SELECTION OF PATIENTS FOR TREATMENT WITH CB1R ANTAGONISTS

Country Status (6)

Country Link
AR (1) AR067628A1 (en)
CL (1) CL2008001972A1 (en)
PE (1) PE20090442A1 (en)
TW (1) TW200914046A (en)
UY (1) UY31202A1 (en)
WO (1) WO2009004380A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019090671A (en) * 2017-11-14 2019-06-13 国立大学法人名古屋大学 Method for diagnosing inflammation
CN108020625A (en) * 2017-12-01 2018-05-11 上海宝藤生物医药科技股份有限公司 Method for detecting contents of arachidonic acid ethanolamine and 2-arachidonic acid glycerol in blood plasma and threatened abortion diagnostic kit

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7955816B2 (en) * 2006-05-02 2011-06-07 Universita Degli Studi Di Roma “Tor Vergata” Design and synthesis of biotinylated probes for N-acyl-ethanolamines

Also Published As

Publication number Publication date
AR067628A1 (en) 2009-10-21
CL2008001972A1 (en) 2009-06-26
PE20090442A1 (en) 2009-05-17
TW200914046A (en) 2009-04-01
WO2009004380A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
ES2422735T3 (en) Procedure for predicting a risk of adverse drug reactions by determining HLA-B 1502
CY1123776T1 (en) METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2-INDEPENDENT COMPLEMENT ACTIVATION
BR112015021759A2 (en) shoe article incorporating a knitted component with integrally knitted thread portion
CL2015002127A1 (en) Systems and methods for clinical decision support.
BR112015022776A2 (en) sole structures and footwear having lightweight midsole elements with protective elements
CL2019001475A1 (en) Methods to treat inflammatory conditions.
AR095363A1 (en) BIOMARKERS AND METHODS FOR THE TREATMENT OF CONDITIONS RELATED TO PD-1 AND PD-L1
CY1109321T1 (en) Combination therapy for the treatment of diabetes and related diseases with this and for the treatment of conditions that improve
CO2020001012A2 (en) Bifunctional compounds
BR112013023841A2 (en) elevator system
UY32085A (en) KINASE INHIBITORS AND METHODS FOR USE
CL2009000545A1 (en) Use of a c-met antagonist and a her antagonist for the treatment of cancer.
SMP201100003B (en) Aryl GPR119 receptor agonists and their uses
AR099883A1 (en) COMPUTER AND METHODS RELATED TO THE PROSTATE CANCER DIAGNOSIS
CY1124140T1 (en) DIAGNOSTIC INDICATORS FOR THE THERAPEUTIC TREATMENT OF HYPERPLASTIC CELL DISORDERS WITH TELOMERASE INHIBITORS
CL2008002368A1 (en) Use of gaboxadol to prepare a medicine useful in the treatment of depression in patients who have one or more elevated or abnormal inflammatory markers.
UY32214A (en) S1P RECEIVER AGONISTS FOR THE TREATMENT OF CEREBRAL MALARIA
ECSP10010409A (en) CxCR3 CHEMIOKIN RECEIVER INHIBITORS
UY28650A1 (en) MEMANTINE FOR THE PREVENTION OR DECREASE OF SUICIDE CONDUCT AND FOR THE TREATMENT OF THE MAJOR DEPRESSION ASSOCIATED WITH THIS CONDUCT
BR112015008042A2 (en) complementary diagnoses for tec family kinase inhibitor therapy
CO2018006298A2 (en) Lactoferrin for use in the diagnosis or prognosis of Alzheimer's disease or in the diagnosis of parkinson's disease
AR054357A1 (en) METHOD TO EVALUATE THE EFFECTIVENESS OF A TREATMENT REGIME
PE20150765A1 (en) ANTIANDROGENS FOR THE TREATMENT OF CASTRATION-RESISTANT NON-METASTASIC PROSTATE CANCER
ES2570631T3 (en) Apolipoprotein AII determination procedure for in vitro diagnosis of colorectal cancer
UY31202A1 (en) BIOMARKERS FOR THE SELECTION OF PATIENTS FOR TREATMENT WITH CB1R ANTAGONISTS

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120613